AcelRx Pharma Plans to Resubmit New Drug Application for Dsuvia Post author:Sam Post published:March 8, 2018 Post category:BioPharma AcelRx Pharmaceuticals plans to resubmit the NDA for Dsuvia in the second quarter of this year. Source: BioSpace You Might Also Like MilliporeSigma Launches Industry's First Off-the-Shelf Cell Culture Media for Perfusion Processes May 14, 2017 Confident Bristol-Myers to Launch 700-Patient Phase III IDO Trial for Melanoma November 6, 2017 ProQR Therapeutics Spins Out CNS-Focused Biotech, September 11, 2017
MilliporeSigma Launches Industry's First Off-the-Shelf Cell Culture Media for Perfusion Processes May 14, 2017